Immuntherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2019
Standard
Immuntherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2019. / Doescher, J; Busch, C-J; Wollenberg, B; Dietz, A; Würdemann, N; Schuler, P; Hoffmann, T K; Laban, S.
In: HNO, Vol. 67, No. 12, 12.2019, p. 905-911.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Immuntherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2019
AU - Doescher, J
AU - Busch, C-J
AU - Wollenberg, B
AU - Dietz, A
AU - Würdemann, N
AU - Schuler, P
AU - Hoffmann, T K
AU - Laban, S
PY - 2019/12
Y1 - 2019/12
N2 - BACKGROUND: In the field of immunotherapy of head and neck squamous cell carcinoma (HNSCC), a high level of study activity can still be observed. The results of the Keynote-048 study on first-line therapy with pembrolizumab were a highlight at this year's meeting of the American Society of Clinical Oncology (ASCO).MATERIALS AND METHODS: All abstracts and presentations on immunotherapy of head and neck tumors presented at ASCO 2019 were evaluated for relevance and the most interesting studies were summarized.RESULTS: The Keynote-048 study showed an improvement in overall survival with pembrolizumab monotherapy for patients with measurable programmed cell death ligand 1 (PD-L1) expression according to the combined positive score (CPS), and for the whole cohort with the combination of pembrolizumab and platin/5-fluorouracil (FU). The EAGLE study on durvalumab ± tremelimumab in second-line therapy did not demonstrate any improvement in response rates or overall survival compared to standard therapy. In addition, several new immunotherapeutic approaches and combinations were presented.CONCLUSION: The results of the Keynote-048 study have already led to the approval of pembrolizumab in the first line for platin-sensitive HNSCC in the USA and the expected approval in Europe will presumably change the therapeutic landscape in the long term. In the future, effective therapies for patients without a response to programmed cell death 1 (PD-1)/PD-L1 inhibition will be needed.
AB - BACKGROUND: In the field of immunotherapy of head and neck squamous cell carcinoma (HNSCC), a high level of study activity can still be observed. The results of the Keynote-048 study on first-line therapy with pembrolizumab were a highlight at this year's meeting of the American Society of Clinical Oncology (ASCO).MATERIALS AND METHODS: All abstracts and presentations on immunotherapy of head and neck tumors presented at ASCO 2019 were evaluated for relevance and the most interesting studies were summarized.RESULTS: The Keynote-048 study showed an improvement in overall survival with pembrolizumab monotherapy for patients with measurable programmed cell death ligand 1 (PD-L1) expression according to the combined positive score (CPS), and for the whole cohort with the combination of pembrolizumab and platin/5-fluorouracil (FU). The EAGLE study on durvalumab ± tremelimumab in second-line therapy did not demonstrate any improvement in response rates or overall survival compared to standard therapy. In addition, several new immunotherapeutic approaches and combinations were presented.CONCLUSION: The results of the Keynote-048 study have already led to the approval of pembrolizumab in the first line for platin-sensitive HNSCC in the USA and the expected approval in Europe will presumably change the therapeutic landscape in the long term. In the future, effective therapies for patients without a response to programmed cell death 1 (PD-1)/PD-L1 inhibition will be needed.
KW - Congresses as Topic
KW - Europe
KW - Head and Neck Neoplasms
KW - Humans
KW - Immunologic Factors
KW - Immunotherapy/methods
KW - Squamous Cell Carcinoma of Head and Neck
U2 - 10.1007/s00106-019-00761-8
DO - 10.1007/s00106-019-00761-8
M3 - SCORING: Review
C2 - 31612261
VL - 67
SP - 905
EP - 911
JO - HNO
JF - HNO
SN - 0017-6192
IS - 12
ER -
